Industry News (Vaccine Development)

Bispecific Technology Produces Vaccine-Like Effect

Published in Cancer Weekly, January 29th, 1996

Medarex, Inc., Annandale, New Jersey, announced that new scientific studies demonstrate that its Bispecific technology is able to stimulate a potent immune response against targeted antigens, thus causing a vaccine-like effect.

The results appear in the January 15, 1996, issue of The Journal of Clinical Investigation. In these in vivo studies, a team of academic and Medarex scientists led by Professor Jan G.J. van de Winkel of Utrecht University, developed transgenic mice whose white blood cells are genetically modified to express human Fc receptors; these modifications allow the mice to be used as a model system for testing the Bispecifics which have been developed by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry